HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Takeda's $4B TYK2 drug tops Bristol Myers' Sotyktu in head-to-head test

The results support Takeda's long-held belief in zasocitinib's superiority and could help it gain a commercial advantage over Bristol's therapy.

By BioPharma Dive · Jun 11, 2026 · via BioPharma Dive
Takeda's $4B TYK2 drug tops Bristol Myers' Sotyktu in head-to-head test

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Regulatory tracker: Novo's oral GLP-1 picks up UK approval
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansion…
Jun 14, 2026
'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff
The WeekFierceBiotech ↗
'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevi…
Jun 14, 2026
STAT’s focus: Obesity drugs crowd pipeline as peptides gain ground
The WeekBriefing
STAT’s focus: Obesity drugs crowd pipeline as peptides gain ground
STAT News spotlighted obesity drugs in development, peptide therapies going mainstream, and a record biotech I…
Jun 14, 2026